Traduction de «a10ba02 » (Néerlandais → Français) :

A10BA02 METFORMINE 403.194 82,4% 72,0% A10BB01 GLIBENCLAMIDE 9.423 1,9% 1,7% A10BB07 GLIPIZIDE 2.752 0,6% 0,5% A10BB08 GLIQUIDON 37.119 7,6% 6,6% A10BB09 GLICLAZIDE 102.965 21,0% 18,4% A10BB12 GLIMEPIRIDE 21.232 4,3% 3,8% A10BD02 METFORMINE MET SULFONYLUREUMDERIVATEN 15.272 3,1% 2,7% A10BD03 METFORMINE MET ROSIGLITAZON 658 0,1% 0,1% A10BD07 METFORMINE MET SITAGLIPTINE 288 0,1% 0,1% A10BD08 METFORMINE EN VILDAGLIPTINE 1.199 0,2% 0,2% A10BG02 ROSIGLITAZON 8.560 1,7% 1,5% A10BG03 PIOGLITAZON 2.097 0,4% 0,4% A10BH01 SITAGLIPTINE 17.244 3,5% 3,1% A10BH02 VILDAGLIPTINE 7.041 1,4% 1,3% A10BH03 SAXAGLIPTINE 2.478 0,5% 0,4% A10BX02 REPAGLINIDE 47.839 9,8% 8,5% A10BX04 EXENATIDE 5.407 1,1% 1,0% A10BX07 LIRAGLUTIDE 1.758 0,4% 0,3%
A10B HYPOGLYCEMIANTS ORAUX 489.559 100,0% 87,4% Dont ceux qui ne prennent pas d'insulines et analogues : 423.454 86,5% 75,6% A10BA02 METFORMINE 403.194 82,4% 72,0% A10BB01 GLIBENCLAMIDE 9.423 1,9% 1,7% A10BB07 GLIPIZIDE 2.752 0,6% 0,5% A10BB08 GLIQUIDONE 37.119 7,6% 6,6% A10BB09 GLICLAZIDE 102.965 21,0% 18,4% A10BB12 GLIMEPIRIDE 21.232 4,3% 3,8% A10BD02 METFORMINE ET DERIVES DE LA SULFONYLUREE 15.272 3,1% 2,7% A10BD03 METFORMINE ET ROSIGLITAZONE 658 0,1% 0,1% A10BD07 METFORMINE ET SITAGLIPTINE 288 0,1% 0,1% A10BD08 METFORMINE ET VILDAGLIPTINE 1.199 0,2% 0,2% A10BG02 ROSIGLITAZONE 8.560 1,7% 1,5% A10BG03 PIOGLITAZONE 2.097 0,4% 0,4% A10BH01 SITAGLIPTINE 17.244 3,5% 3,1% A10BH02 VILDAGLIPTINE 7.041 1,4% 1,3% A10BH03 SAXAGLIPTINE 2.478 0,5% 0,4% A10BX02 REPAGLINIDE 47.839 9,8% 8,5% A10BX04 EXENATIDE 5.407 1,1% 1,0% A10BX07 LIRAGLUTIDE 1.758 0,4% 0,3%

C02DB02 A01AC03; A07EA02; C05AA01; D07AA02; H02AB09; S01BA02; S02BA01 A01AC03; A07EA02; C05AA01; D07AA02; H02AB09; S01BA02; S02BA01 D05AA99B; D10BX01 A16AX79B; C01EB03; M01AB01; S01BC01 J04AC01 A12BA01 S01XA04; V03AB21 D08AX06; V03AB18 C01BA01 P01BC01 N02BG99B; P01BC01 A02DA99B D05AA97B V03AB20 D04AX98B C01BB01; C05AD01; D04AB01; N01BB02; R02AD02; S01HA07; S02DA01 C01BB01; C05AD01; D04AB01; N01BB02; R02AD02; S01HA07; S02DA01 N05AN01 G03AC06; G03DA02; L02AB02 A10BA02 N02AC02 D07AA01; H02AB04 A01AB17; D06BX01; G01AF01; J01XD01 A01AB09; A07AC01; D01AC02; G01AF04; J02AB01; S02AA13 J01AA08 A07DA52; N02AA01 A12CA01 A06AG01 N03AB02 A12CD01 S01AX10 B05CB04 A07AA01; J01GB05; R02AB01; S02AA07; A07AA02; D01AA01; G01AA01 N02BE01 N02BE01 M01CC01 S01EB01; N07AX01 A07AA05; J01XB02; S01AA18; S02AA11; S03AA03 A07EA01; C05AA04; D07AA03; H02AB06; R01AD02; S01BA04; S02BA03; S03BA02 A07EA01; C05AA04; D07AA03; H02AB06; R01AD02; S01BA04; S02BA03; S03BA02 A07EA01; C05AA04; D07AA03; H02AB06; R01AD02; S01BA04; S02BA03; S03BA02 A07EA03; H02AB07 M04AB01 C05AD05; N01BA02; S01HA05 D04AA10; R06AD02 A03AB05 H03BA02 A02BA02 S01AX06 V07AW99B D01AE12; D02AF99B; S01BC08 A03BB01 C03DA01
D05AA97B N05AD01 C02DB02 A01AC03; A07EA02; C05AA01; D07AA02; H02AB09; S01BA02; S02BA01 A01AC03; A07EA02; C05AA01; D07AA02; H02AB09; S01BA02; S02BA01 D05AA99B; D10BX01 A16AX79B; C01EB03; M01AB01; S01BC01 J04AC01 D04AX98B C01BB01; C05AD01; D04AB01; N01BB02; R02AD02; S01HA07; S02DA01 C01BB01; C05AD01; D04AB01; N01BB02; R02AD02; S01HA07; S02DA01 N05AN01 G03AC06; G03DA02; L02AB02 A10BA02 N02AC02 D07AA01; H02AB04 A01AB17; D06BX01; G01AF01; J01XD01 A01AB09; A07AC01; D01AC02; G01AF04; J02AB01; S02AA13 J01AA08 A07DA52; N02AA01 A07AA01; J01GB05; R02AB01; S02AA07; A07AA02; D01AA01; G01AA01 N02BE01 N02BE01 M01CC01 J01CE02 N03AB02 N03AB02 S01EB01; N07AX01 A07AA05; J01XB02; S01AA18; S02AA11; S03AA03 A12BA01 S01XA04; V03AB21 D08AX06; V03AB18 A07EA01; C05AA04; D07AA03; H02AB06; R01AD02; S01BA04; S02BA03; S03BA02 A07EA01; C05AA04; D07AA03; H02AB06; R01AD02; S01BA04; S02BA03; S03BA02 A07EA01; C05AA04; D07AA03; H02AB06; R01AD02; S01BA04; S02BA03; S03BA02 A07EA03; H02AB07 M04AB01 C05AD05; N01BA02; S01HA05 D04AA10; R06AD02 A03AB05 H03BA02 C01BA01 P01BC01 N02BG99B; P01BC01 A02BA02 S01AX06 V07AW99B D01AE12; D02AF99B; S01BC08 A03BB01 B05CB04 A12CA01 A12CD01 A06AG01 S01AX10

Aantal Geneesmiddelen tegen diabetes patiënten 2006 A10AB01 HUMANE INSULINE (fast-acting) 28.839 A10AB04 INSULINE LISPRO (fast-acting) 4.984 A10AB05 INSULINE ASPART (fast-acting) 20.762 A10AC01 HUMANE INSULINE (intermediate-acting) 29.453 A10AD01 HUMANE INSULINE (intermediate+fast-acting) 55.183 A10AD05 INSULINE ASPART (intermediate+fast-acting) 7.733 A10AE01 HUMANE INSULINE (long-acting) 577 A10AE04 INSULINE GLARGINE (long-acting) 27.011 A10AE05 INSULINE DETEMIR (long-acting) 6.166 A10A INSULINES EN ANALOGEN aantal hiervan dat geen hypoglykemiërende middelen gebruikt 114.589 61.393 A10BA02 METFORMINE 270.080 A10BB01 GLIBENCLAMIDE 15.814 A10BB07 GLIPIZIDE 5.013 A10BB08 GLIQUIDON 39.358 A10BB09 GLICLAZIDE 91.791 A10BB12 GLIMEPIRIDE 26.516 A10BD02 METFORMINE MET SULFONYLUREUMDERIVATEN 17.367 A10BD03 METFORMINE MET ROSIGLITAZON 498 A10BG02 ROSIGLITAZON 14.168 A10BG03 PIOGLITAZON 1.816 A10BX02 REPAGLINIDE 41.132 A10B HYPOGLYKEMIERENDE MIDDELEN MET UITZONDERING VAN INSULINES 375.137
A10AB01 INSULINE HUMAINE (fast-acting) 28.839 A10AB04 INSULINE LISPRO (fast-acting) 4.984 A10AB05 INSULINE ASPARTE (fast-acting) 20.762 A10AC01 INSULINE HUMAINE (intermediate-acting) 29.453 A10AD01 INSULINE HUMAINE (intermediate+fast-acting) 55.183 A10AD05 INSULINE ASPART (intermediate+fast-acting) 7.733 A10AE01 INSULINE HUMAINE (long-acting) 577 A10AE04 INSULINE GLARGINE (long-acting) 27.011 A10AE05 INSULINE DETEMIR (long-acting) 6.166 A10A INSULINES ET ANALOGUES Dont ceux qui ne prennent pas d'hypoglycémiant oraux : 114.589 61.393 A10BA02 METFORMINE 270.080 A10BB01 GLIBENCLAMIDE 15.814 A10BB07 GLIPIZIDE 5.013 A10BB08 GLIQUIDONE 39.358 A10BB09 GLICLAZIDE 91.791 A10BB12 GLIMEPIRIDE 26.516 A10BD02 METFORMINE ET DERIVES DE LA SULFONYLUREE 17.367 A10BD03 METFORMINE ET ROSIGLITAZONE 498 A10BG02 ROSIGLITAZONE 14.168 A10BG03 PIOGLITAZONE 1.816 A10BX02 REPAGLINIDE 41.132 A10B HYPOGLYCEMIANTS ORAUX 375.137

Aantal Geneesmiddelen tegen diabetes patiënten 2007 A10AB01 HUMANE INSULINE (fast-acting) 27.972 A10AB04 INSULINE LISPRO (fast-acting) 5.083 A10AB05 INSULINE ASPART (fast-acting) 24.718 A10AB06 INSULINE GLULISINE (fast-acting) 997 A10AC01 HUMANE INSULINE (intermediate-acting) 28.656 A10AD01 HUMANE INSULINE (intermediate+fast-acting) 53.714 A10AD05 INSULINE ASPART (intermediate+fast-acting) 10.655 A10AE01 HUMANE INSULINE (long-acting) 122 A10AE04 INSULINE GLARGINE (long-acting) 30.567 A10AE05 INSULINE DETEMIR (long-acting) 7.577 A10A INSULINES EN ANALOGEN 120.352 aantal hiervan dat geen orale antidiabetica gebruikt 62.933 A10BA02 METFORMINE 295.576 A10BB01 GLIBENCLAMIDE 13.827 A10BB07 GLIPIZIDE 4.303 A10BB08 GLIQUIDON 39.384 A10BB09 GLICLAZIDE 93.905 A10BB12 GLIMEPIRIDE 24.927 A10BD02 METFORMINE MET SULFONYLUREUMDERIVATEN 17.041 A10BD03 METFORMINE MET ROSIGLITAZON 717 A10BG02 ROSIGLITAZON 15.014 A10BG03 PIOGLITAZON 1.902 A10BX02 REPAGLINIDE 45.903 A10B ORALE ANTIDIABETICA MET UITZONDERING VAN INSULINES 397.270 Aantal hiervan dat geen insulines en analogen gebruikt 339.851
Médicaments contre le diabète Nombre de patients 2007 A10AB01 INSULINE HUMAINE (fast-acting) 27.972 A10AB04 INSULINE LISPRO (fast-acting) 5.083 A10AB05 INSULINE ASPARTE (fast-acting) 24.718 A10AB06 INSULINE GLULISINE (fast-acting) 997 A10AC01 INSULINE HUMAINE (intermediate-acting) 28.656 A10AD01 INSULINE HUMAINE (intermediate+fast-acting) 53.714 A10AD05 INSULINE ASPART (intermediate+fast-acting) 10.655 A10AE01 INSULINE HUMAINE (long-acting) 122 A10AE04 INSULINE GLARGINE (long-acting) 30.567 A10AE05 INSULINE DETEMIR (long-acting) 7.577 A10A INSULINES ET ANALOGUES 120.352 Dont ceux qui ne prennent pas d'antidiabétiques oraux : 62.933 A10BA02 METFORMINE 295.576 A10BB01 GLIBENCLAMIDE 13.827 A10BB07 GLIPIZIDE 4.303 A10BB08 GLIQUIDONE 39.384 A10BB09 GLICLAZIDE 93.905 A10BB12 GLIMEPIRIDE 24.927 A10BD02 METFORMINE ET DERIVES DE LA SULFONYLUREE 17.041 A10BD03 METFORMINE ET ROSIGLITAZONE 717 A10BG02 ROSIGLITAZONE 15.014 A10BG03 PIOGLITAZONE 1.902 A10BX02 REPAGLINIDE 45.903 A10B ANTIDIABETIQUES ORAUX 397.270 Dont ceux qui ne prennent pas d'insulines et analogues : 339.851

A10AB01 HUMANE INSULINE (fast-acting) 27.240 A10AB04 INSULINE LISPRO (fast-acting) 5.583 A10AB05 INSULINE ASPART (fast-acting) 29.705 A10AB06 INSULINE GLULISINE (fast-acting) 2.239 A10AC01 HUMANE INSULINE (intermediate-acting) 27.481 A10AD01 HUMANE INSULINE (intermediate+fast-acting) 50.278 A10AD04 INSULINE LISPRO 2.627 A10AD05 INSULINE ASPART (intermediate+fast-acting) 15.565 A10AE04 INSULINE GLARGINE (long-acting) 35.968 A10AE05 INSULINE DETEMIR (long-acting) 8.770 A10A INSULINES EN ANALOGEN 129.478 Aantal hiervan dat geen hypoglykemiërende middelen gebruikt 67.473 A10BA02 METFORMINE 341.879 A10BB01 GLIBENCLAMIDE 12.565 A10BB07 GLIPIZIDE 3.795 A10BB08 GLIQUIDON 39.952 A10BB09 GLICLAZIDE 99.680 A10BB12 GLIMEPIRIDE 24.522 A10BD02 METFORMINE MET SULFONYLUREUMDERIVATEN 17.373 A10BD03 METFORMINE MET ROSIGLITAZON 769 A10BG02 ROSIGLITAZON 13.684 A10BG03 PIOGLITAZON 1.841 A10BH01 SITAGLIPTINE 6.249 A10BX02 REPAGLINIDE 50.192 A10BX04 EXENATIDE 2.461 A10B HYPOGLYKEMIERENDE MIDDELEN MET UITZONDERING VAN INSULINES 441.869 Aantal hiervan dat geen insulines en analogen gebruikt 379.864
Nombre de Médicaments contre le diabète patients 2008 A10AB01 INSULINE HUMAINE (fast-acting) 27.240 A10AB04 INSULINE LISPRO (fast-acting) 5.583 A10AB05 INSULINE ASPARTE (fast-acting) 29.705 A10AB06 INSULINE GLULISINE (fast-acting) 2.239 A10AC01 INSULINE HUMAINE (intermediate-acting) 27.481 A10AD01 INSULINE HUMAINE (intermediate+fast-acting) 50.278 A10AD05 INSULINE ASPART (intermediate+fast-acting) 2.627 A10AE01 INSULINE HUMAINE (long-acting) 15.565 A10AE04 INSULINE GLARGINE (long-acting) 35.968 A10AE05 INSULINE DETEMIR (long-acting) 8.770 A10A INSULINES ET ANALOGUES Dont ceux qui ne prennent pas d'hypoglycémiant oraux : 129.478 67.473 A10BA02 METFORMINE 341.879 A10BB01 GLIBENCLAMIDE 12.565 A10BB07 GLIPIZIDE 3.795 A10BB08 GLIQUIDONE 39.952 A10BB09 GLICLAZIDE 99.680 A10BB12 GLIMEPIRIDE 24.522 A10BD02 METFORMINE ET DERIVES DE LA SULFONYLUREE 17.373 A10BD03 METFORMINE ET ROSIGLITAZONE 769 A10BG02 ROSIGLITAZONE 13.684 A10BG03 PIOGLITAZONE 1.841 A10BH01 SITAGLIPTINE 6.249 A10BX02 REPAGLINIDE 50.192 A10BX04 EXENATIDE 2.461 A10B HYPOGLYCEMIANTS ORAUX Dont ceux qui ne prennent pas d'insulines et analogues : 441.869 379.864

Aantal Geneesmiddelen tegen diabetes patiënten 2005 A10AB01 HUMANE INSULINE (fast-acting) 30.110 A10AB04 INSULINE LISPRO (fast-acting) 5.078 A10AB05 INSULINE ASPART (fast-acting) 16.638 A10AC01 HUMANE INSULINE (intermediate-acting) 32.744 A10AD01 HUMANE INSULINE (intermediate+fast-acting) 56.796 A10AD05 INSULINE ASPART (intermediate+fast-acting) 5.979 A10AE01 HUMANE INSULINE (long-acting) 788 A10AE04 INSULINE GLARGINE (long-acting) 24.161 A10AE05 INSULINE DETEMIR (long-acting) 1.841 A10A INSULINES EN ANALOGEN 110.007 aantal hiervan dat geen hypoglykemiërende middelen gebruikt 60.190 A10BA02 METFORMINE 251.410 A10BB01 GLIBENCLAMIDE 18.492 A10BB07 GLIPIZIDE 5.995 A10BB08 GLIQUIDON 39.557 A10BB09 GLICLAZIDE 90.936 A10BB12 GLIMEPIRIDE 27.961 A10BD02 METFORMINE MET SULFONYLUREUMDERIVATEN 16.042 A10BD03 METFORMINE MET ROSIGLITAZON 289 A10BG02 ROSIGLITAZON 12.871 A10BG03 PIOGLITAZON 1.800 A10BX02 REPAGLINIDE 38.748 A10B HYPOGLYKEMIERENDE MIDDELEN MET UITZONDERING VAN INSULINES 357.775 Aantal hiervan dat geen insulines en analogen gebruikt 307.958
A10AB01 INSULINE HUMAINE (fast-acting) 30.110 A10AB04 INSULINE LISPRO (fast-acting) 5.078 A10AB05 INSULINE ASPARTE (fast-acting) 16.638 A10AC01 INSULINE HUMAINE (intermediate-acting) 32.744 A10AD01 INSULINE HUMAINE (intermediate+fast-acting) 56.796 A10AD05 INSULINE ASPART (intermediate+fast-acting) 5.979 A10AE01 INSULINE HUMAINE (long-acting) 788 A10AE04 INSULINE GLARGINE (long-acting) 24.161 A10AE05 INSULINE DETEMIR (long-acting) 1.841 A10A INSULINES ET ANALOGUES 110.007 Dont ceux qui ne prennent pas d'hypoglycémiant oraux : 60.190 A10BA02 METFORMINE 251.410 A10BB01 GLIBENCLAMIDE 18.492 A10BB07 GLIPIZIDE 5.995 A10BB08 GLIQUIDONE 39.557 A10BB09 GLICLAZIDE 90.936 A10BB12 GLIMEPIRIDE 27.961 A10BD02 METFORMINE ET DERIVES DE LA SULFONYLUREE 16.042 A10BD03 METFORMINE ET ROSIGLITAZONE 289 A10BG02 ROSIGLITAZONE 12.871 A10BG03 PIOGLITAZONE 1.800 A10BX02 REPAGLINIDE 38.748 A10B HYPOGLYCEMIANTS ORAUX 357.775 Dont ceux qui ne prennent pas d'insulines et analogues : 307.958

Aantal Geneesmiddelen tegen diabetes patiënten 2009 A10AB01 HUMANE INSULINE (fast-acting) 25.472 A10AB04 INSULINE LISPRO (fast-acting) 5.805 A10AB05 INSULINE ASPART (fast-acting) 32.502 A10AB06 INSULINE GLULISINE (fast-acting) 3.957 A10AC01 HUMANE INSULINE (intermediate-acting) 25.714 A10AD01 HUMANE INSULINE (intermediate+fast-acting) 43.558 A10AD04 INSULINE LISPRO (fast-acting) 3.082 A10AD05 INSULINE ASPART (intermediate+fast-acting) 23.041 A10AE04 INSULINE GLARGINE (long-acting) 39.609 A10AE05 INSULINE DETEMIR (long-acting) 9.324 A10A INSULINES EN ANALOGEN aantal hiervan dat geen hypoglykemiërende middelen gebruikt 132.855 68.954 A10BA02 METFORMINE 371.639 A10BB01 GLIBENCLAMIDE 10.814 A10BB07 GLIPIZIDE 3.174 A10BB08 GLIQUIDON 38.586 A10BB09 GLICLAZIDE 102.103 A10BB12 GLIMEPIRIDE 22.804 A10BD02 METFORMINE MET SULFONYLUREUMDERIVATEN 16.231 A10BD03 METFORMINE MET ROSIGLITAZON 755 A10BD08 METFORMINE EN VILDAGLIPTINE 327 A10BG02 ROSIGLITAZON 10.971 A10BG03 PIOGLITAZON 1.534 A10BH01 SITAGLIPTINE 10.689 A10BH02 VILDAGLIPTINE 3.244 A10BX02 REPAGLINIDE 49.667 A10BX04 EXENATIDE 4.646 A10B HYPOGLYKEMIERENDE MIDDELEN MET UITZONDERING VAN INSULINES Aantal hiervan dat geen insulines en analogen gebruikt 465.497 401.596
Nombre de Médicaments contre le diabète patients 2009 A10AB01 INSULINE HUMAINE (fast-acting) 25.472 A10AB04 INSULINE LISPRO (fast-acting) 5.805 A10AB05 INSULINE ASPARTE (fast-acting) 32.502 A10AB06 INSULINE GLULISINE (fast-acting) 3.957 A10AC01 INSULINE HUMAINE (intermediate-acting) 25.714 A10AD01 INSULINE HUMAINE (intermediate+fast-acting) 43.558 A10AD04 INSULINE LISPRO (intermediate+fast-acting) 3.082 A10AD05 INSULINE ASPARTE (intermediate+fast-acting) 23.041 A10AE04 INSULINE GLARGINE (long-acting) 39.609 A10AE05 INSULINE DETEMIR (long-acting) 9.324 A10A INSULINES ET ANALOGUES Dont ceux qui ne prennent pas d'hypoglycémiant oraux : 132.855 68.954 A10BA02 METFORMINE 371.639 A10BB01 GLIBENCLAMIDE 10.814 A10BB07 GLIPIZIDE 3.174 A10BB08 GLIQUIDONE 38.586 A10BB09 GLICLAZIDE 102.103 A10BB12 GLIMEPIRIDE 22.804 A10BD02 METFORMINE ET DERIVES DE LA SULFONYLUREE 16.231 A10BD03 METFORMINE ET ROSIGLITAZONE 755 A10BD08 METFORMINE ET VILDAGLIPTINE 327 A10BG02 ROSIGLITAZONE 10.971 A10BG03 PIOGLITAZONE 1.534 A10BH01 SITAGLIPTINE 10.689 A10BH02 VILDAGLIPTINE 3.244 A10BX02 REPAGLINIDE 49.667 A10BX04 EXENATIDE 4.646 A10B HYPOGLYCEMIANTS ORAUX Dont ceux qui ne prennent pas d'insulines et analogues : 465.497 401.596

5. FARMACOLOGISCHE EIGENSCHAPPEN 5.1. Farmacodynamische eigenschappen Farmacotherapeutische categorie: orale bloedglucose verlagende middelen, biguaniden ATC-code : A10BA02 Metformine is een biguanide met bloedglucoseverlagende effecten dat zowel de basale als de postprandiale plasmaglucosewaarden verlaagt.
5.1. Propriétés pharmacodynamiques Classe pharmacothérapeutique : antidiabétiques oraux, biguanides Code ATC : A10BA02 La metformine est un biguanide possédant des effets anti-hyperglycémiants, réduisant la glycémie basale et postprandiale.

Farmacotherapeutische categorie: orale bloedglucoseverlagende stoffen, biguaniden. ATC code: A10BA02 Metformine is een biguanide met bloedglucoseverlagende effecten en verlaagt zowel basale als postprandiale plasmaglucosewaarden.
La metformine est un biguanide possédant des effets antihyperglycémiants, réduisant la glycémie basale et postprandiale.

Pharmacotherapeutische klasse: A10BA02 : gastro-intestinaal stelsel en metabolisme.
Classe pharmacothérapeutique : A10BA02: Tractus gastro-intestinal et metabolisme